SCHEMBL2660707

SCHEMBL2660707

CCCN1Cc2nc3c(-c4ccc(C)cc4)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CRHR1 P34998 2/20 0.41
▸ GAA P10253 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ENPP1 P22413 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ GABRG2 P18507 3/20 0.34
▸ GABRB3 P28472 3/20 0.34
▸ GABRA2 P47869 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HRH4 Q9H3N8 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPK10 P53779 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660713 0.92 HRH4 (0.42) CRHR1GAAALDH1A1ENPP1LMNA
SCHEMBL2656723 0.91 GABRG2 (0.44) CRHR1GAAALDH1A1NPSR1ENPP1
SCHEMBL2660737 0.91 ENPP1 (0.38) CRHR1GAAALDH1A1ENPP1LMNA
SCHEMBL2660678 0.90 GABRG2 (0.45) CRHR1GAAALDH1A1NPSR1ENPP1
SCHEMBL2660637 0.90 LMNA (0.38) GAAALDH1A1NPSR1LMNAPARP1
SCHEMBL2657821 0.88 LMNA (0.38) CRHR1GAAALDH1A1NPSR1LMNA
SCHEMBL2660653 0.88 HRH4 (0.47) LMNAPARP1HTTPARP2HRH4
SCHEMBL2661290 0.87 GABRG2 (0.46) CRHR1GAAALDH1A1NPSR1LMNA
SCHEMBL2660780 0.86 GABRG2 (0.42) GAAALDH1A1NPSR1LMNAPARP1
SCHEMBL4924382 0.86 LCK (0.49) LMNAPARP1HTTPARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
EP-0245053-B1 HETEROCYCLIC FUSED TRICYCLIC COMPOUNDS ICI AMERICAS INC. (US) 1992-11-25 — — EP disclosed
US-5118688-A TETRAHYDROPYRIDOQUINOLONE DERIVATIVES USEFUL AS ANXIOLYTIC AGENTS ICI AMERICAS INC. (US) 1992-06-02 — — US disclosed
US-4975435-A Certain 1H-pyrrold[3,4-b]quinolin-1-one-9-amino-2,3-dihydro derivatives useful for treating anxiety ICI AMERICAS INC. (US) 1990-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF CRHR1 60/4885GAA 271/4885ALDH1A1 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback